National Academy of Inventors’ Post

Proteins are the "workers" in the biochemistry of life and are critical to almost everything your body does, but sometimes, they can also cause or contribute to disease. RNAi therapeutics, which were pioneered by Alnylam, work by preventing the production of specific unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Read more here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science

#LipidNanoparticles, #RNATherapeutics, #QualityAssessment | 𝗛𝗼𝘄 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗶𝘀 𝘁𝗵𝗲 𝗿𝗼𝗹𝗲 𝗼𝗳 𝗿𝗼𝗯𝘂𝘀𝘁 𝗮𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝘁𝗵𝗼𝗱𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀? 🟣 𝗔𝗶𝗺 To assess the quality of lipid nanoparticles (LNPs) used for in-vivo intracellular delivery of nucleic acids through comprehensive analytical methods. 🟣 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀 Evaluation and comparison of analytical protocols for chemical composition, drug loading, particle size, concentration, and stability. Assessment of measurement protocols for reproducibility, robustness, and correlative approaches. 🟣 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲 This research highlights the importance of detailed characterization strategies to support the quality assessment of RNA therapeutics. Check here for more: https://lnkd.in/ectX4Dic Thank you, Jérémie Parot, Dora Mehn, Hanna Jankevics Jones, Natalia Markova, Michele Carboni, Camilla Olaisen, Andrea Draget Hoel, Margret Asa Sigfusdottir, Florian Meier, Roland Drexel, Gabriele Vella, Birgitte Hjelmeland McDonagh, Hansen Terkel, Thanh-Huong Bui, Geir Klinkenberg, Torkild Visnes, sabrina gioria, Patricia Urban Lopez, Adriele Prina Mello, Sven Even F. Borgos, Luigi Calzolai.

Explore our human M1/M2 macrophage polarization in vitro assay. A well-defined in vitro model to test the effect of drug-candidates on the M1/M2 balance!

Patients with Duchenne muscular dystrophy, or #DMD, don’t make enough dystrophin. The dystrophin protein helps keep muscles intact. After four months of taking Avidity’s drug, patients had a 25 percent increase in dystrophin production, reaching dystrophin levels that were 54 percent of normal. Today, Avidity Biosciences, Inc. revealed promising results for its treatment for Duchenne muscular dystrophy, sending this #biotech stock soaring. https://lnkd.in/eQ_Aiuir #RNA #biotechnology #clinicaltrials #medicine #lifescience #stock #stocks #stockmarket #Duchenne #pharma #biopharma #business

From their inception to their remarkable achievements, phosphoramidites have revolutionized oligonucleotide synthesis, inviting us to take a journey through time.🕰️ 1982: Thermo Scientific initiates the production of phosphoramidites. 2003: Thermo Fisher introduces TheraPure phosphoramidites, available for the development of oligonucleotide therapeutics. 2018: The FDA approves Patisiran, the first RNAi drug. As phosphoramidites continue to play a pivotal role in driving advancements in genetic research, personalized medicine, and oligo therapeutics, what do you believe could be next on this timeline? 🔗 Discover our range of phosphoramidites and be part of the future: https://lnkd.in/e72YCAFP

At #Sannova, we understand the pivotal role that sensitivity and selectivity play in the successful development of #OligonucleotideTherapeutics. Accurate detection and quantification of #ASOs, siRNAs and miRNAs at low concentrations are essential for assessing efficacy and toxicity, particularly during PK and TK testing.  Our newest whitepaper delves deeper into this topic, highlighting the importance of bioanalytical and chemical manufacturing control in Oligonucleotide Therapeutic Development and #BioanalyticalExcellence. Download it now for expert insights to drive your research forward.

Curious about how organoids can benefit your drug discovery pipeline? Check out this webinar for a discussion on current research challenges and future directions: https://lnkd.in/g2KjSQuC

Great tools to study immuneresponse!

Working in #covalent #drugdiscovery? The 2nd Covalent Drug Discovery & Development Summit returns to Boston this December to empower drug developers to successfully expand the druggable proteome in cystine, histidine and lysine spaces. See the program here: https://ter.li/dglqnd Here are just 4 sessions jam-packed with new data that your peers are taking their seats for: 🔹 Specific Covalent Targeting of Histidine, Tyrosine & Lysine to Expand the Druggable Proteome - Andrea Zuhl, Hyku Biosciences 🔹 Towards a Chemical Biology Platform for the Systematic Discovery & Evaluation of Novel Covalent Chemistry - Sebastian Essig, Bayer 🔹 Innovating the Development of Covalent Molecular Glues Displaying Improved Efficacy through Specific & Durable Interactions - Stefan Andrew Harry, Harvard University & Mgh Cancer Ctr (Bar-Peled & Liau Lab) 🔹 Chemoproteomic Profiling of Covalent Inhibitors in Multiple Cell Types to Assess Pharmacological Targets & Off-Target Safety Risks - Doug Johnson, Biogen Download full session details: https://ter.li/dglqnd #covalency #undruggable #smallmolecule #cystine #lysine #drugdevelopment

Greetings Connections! Interesting to share my molecular docking experiences with you all! I am performing rigid docking for different oncoproteins with some of the FDA-approved chemotherapeutic drugs as my receptor and ligand. Here, I have performed molecular docking of the PALB2/BRCA2 complex with Abemaciclib drug and analyzed it on Discovery Studio and we can visualize the receptor-ligand interactions on a 2D diagram. I am overwhelmed to share my learnings with you all! Thanks & Regards. #bioinformatics #moleculardocking #oncoproteins #cancergenetics #computationalbiology